Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Positive trial for Neurogen’s insomnia candidate
The primary endpoint of the study measured the efficacy of NG2-73 in reducing time to onset of persistent sleep in a well established clinical model of transient insomnia
The primary endpoint of the study measured the efficacy of NG2-73 in reducing time to onset of persistent sleep in a well established clinical model of transient insomnia
Diatos has acquired rights to the compound in Kaposi’s sarcoma, a type of virus-induced cancer, as well as all other potential indications. Gilead will receive upfront and milestone
Caucasians who carry this gene variation are approximately 1.5 times more likely to have a coronary heart disease (CHD) event, such as a heart attack, than those who
Immunomedics will receive initial cash payments of $38 million and could receive potential milestone payments of up to $145 million in cash and $20 million in equity investments,
The FDA granted the designation because infection with shigatoxin-producing bacteria may result in hemolytic uremic syndrome, a serious condition for which there are no currently available preventative therapies.
The company licensed the rights to commercialize the drug in diabetic neuropathy from North Carolina-based Biostratum, while it acquired the commercial rights to the drug in acute renal
CCR5 antagonists are a new class of antiretroviral compound that have been shown to block entry of the HIV virus into the cell, unlike nearly all of the
GVAX was given the designation as it has shown potential to treat advanced prostate cancer, a life-threatening condition that represents an unmet medical need. The treatment is currently
The purpose of the eight-week study is to assess the efficacy and safety of 20mg of IPL512-602 given once daily as an oral asthma medication. Approximately 200 male
In the study, conducted by Duke University Medical Center, more than 50% of obese patients in the Qnexa treatment group experienced 10% or more total body weight loss